Jay H. Shubrook, DO: Hi. I'm Jay Shubrook, a family physician and professor at Touro University, California. We're here at the 78th American Diabetes Association Scientific Sessions in Orlando, Florida. We're going to continue our discussion about guidelines for diabetes around the world.
Today I'm happy to have with me Dr John Wilding, who is a professor at the University of Liverpool in the United Kingdom. We're going to talk a little bit about the National Institute for Health and Care Excellence (NICE) Guidelines.
Thanks for coming. Tell me about the NICE Guidelines.
NICE Guidelines
John P.H. Wilding, DM, FRCP: The NICE Guidelines are quite interesting and unique in the way they are produced. First, there is a very rigorous review process which looks at all of the evidence, including a cost-effectiveness element and a clinical element. The guideline review committees usually consist of experts in the field, experts in guideline development, and, very importantly, patients with the condition of interest—in this case, type 2 diabetes.
Shubrook: That is interesting—the NICE Guidelines evaluate cost-effectiveness, include patient involvement, and have rigorous review. Who follows the NICE Guidelines? Who are they speaking to?
Wilding:The NICE Guidelines are there to support clinical decision-making for people caring for patients with diabetes in the United Kingdom.
